asciminib
Scemblix
Pharmaceutical company: Novartis
NEW INDICATION & DOSAGE
Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase
Adults: 80 mg PO once daily or 40 mg PO every 12 hours if clinical benefit is observed or until unacceptable toxicity occurs.
Adjust-a-dose: Refer to the manufacturer's instructions for toxicity-related dosage adjustments.
Released: January 2025
Nursing Drug Handbook
© 2025 Wolters Kluwer